As the patents associated with the biologics are set to expire in the near future, a new type of therapy appears on the horizon, and it is quite similar to the biologics. This commentary examines the biomedical and market issues surrounding the advent of biosimilars.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972733 | PMC |
http://dx.doi.org/10.1007/s13555-016-0127-4 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!